Cytotoxic agents comprising new ansamitocin derivatives

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9090629
APP PUB NO 20130323268A1
SERIAL NO

13883344

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IMMUNOGEN INC830 WINTER STREET WALTHAM MA 02451

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chari, Ravi V J Newton, US 102 3814
Widdison, Wayne C Belmont, US 37 927
Wilhelm, Sharon D Arlington, US 5 137

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 28, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00